CymaBay Builds Seladelpar Case In PBC, But Door Not Closed On NASH

30 Jun 2021

The company pointed to cirrhosis benefit and less pruritis in a pooled analysis presented at EASL, which will help it will take on Intercept in primary biliary cholangitis on tolerability, cirrhosis benefit.

Biliary tract — CymaBay hopes to take on Intercept in second-line PBC

For the past year, CymaBay Therapeutics, Inc. has focused on developing its PPAR delta agonist seladapar in primary biliary cholangitis, as it looks to get past the roadblocks it faced in non-alcoholic steatohepatitis. The company is confident that it can take on Intercept Pharmaceuticals, Inc.’s lead in PBC with Ocaliva with seladepar’s better tolerability and benefit in cirrhotic patients – and a pooled analysis presented at the European Association for the Study of Liver meeting suggests it will have the data to do so.

CymaBay’s PBC and NASH programs suffered a major setback in November 2019 when the US Food and Drug Administration placed...